Cargando…

Clinical evaluation of modified invaginated pancreaticojejunostomy for pancreaticoduodenectomy

BACKGROUND: Pancreaticoduodenectomy (PD) remains the major curative operation for malignant neoplasm of pancreas or cancerous tumors near the pancreas. Despite advancements in recent years, the postoperative recurrence rate of these neoplasms and tumors remains high. Moreover, overall morbidity rema...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Dong, Liu, Xiao, Wu, Hongwei, Liu, Kun, Zhou, Xiaona, Liu, Jun, Guo, Wei, Zhang, Zhongtao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7161299/
https://www.ncbi.nlm.nih.gov/pubmed/32295594
http://dx.doi.org/10.1186/s12957-020-01851-6
_version_ 1783522934846914560
author Wang, Dong
Liu, Xiao
Wu, Hongwei
Liu, Kun
Zhou, Xiaona
Liu, Jun
Guo, Wei
Zhang, Zhongtao
author_facet Wang, Dong
Liu, Xiao
Wu, Hongwei
Liu, Kun
Zhou, Xiaona
Liu, Jun
Guo, Wei
Zhang, Zhongtao
author_sort Wang, Dong
collection PubMed
description BACKGROUND: Pancreaticoduodenectomy (PD) remains the major curative operation for malignant neoplasm of pancreas or cancerous tumors near the pancreas. Despite advancements in recent years, the postoperative recurrence rate of these neoplasms and tumors remains high. Moreover, overall morbidity remains high due to clinically relevant postoperative pancreatic fistula (POPF). METHODS: To compare the clinical outcomes of modified invaginated anastomosis and mucosa-to-mucosa anastomosis, this retrospective study included 343 patients who underwent PD from January 2008 to January 2019 at Beijing Friendship Hospital, Capital Medical University. The patients’ general conditions and disease status were preoperatively evaluated. The surgical procedure was recorded, and operative management was appropriately performed. RESULTS: Compared with mucosa-to-mucosa anastomosis, modified invaginated anastomosis resulted in a higher intraoperative blood transfusion rate (P < 0.001) and lower hospitalization expenses (P = 0.049). However, no significant differences were found in operation time (P = 0.790), intraoperative bleeding (P = 0.428), postoperative recovery exhaust time (P = 0.442), time to normal flow of food (P = 0.163), and hospitalization time (P = 0.567). Operation time was a risk factor for POPF (odds ratio 1.010; 95% confidence interval 1.003–1.016; P = 0.003). The incidence of pancreatic fistula (grades B and C) was lower in the patients who underwent modified invaginated anastomosis (14.1%) than in those who underwent mucosa-to-mucosa anastomosis (15.3%). The operation time was greater in the POPF group than in the non POPF group among the patients who received modified invaginated anastomosis (P = 0.003) and mucosa-to-mucosa anastomosis (P = 0.002). CONCLUSION: Modified invaginated pancreaticojejunostomy for PD resulted in a decreased incidence of POPF; it may serve as a new approach for PD while managing patients who have undergone PD.
format Online
Article
Text
id pubmed-7161299
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-71612992020-04-22 Clinical evaluation of modified invaginated pancreaticojejunostomy for pancreaticoduodenectomy Wang, Dong Liu, Xiao Wu, Hongwei Liu, Kun Zhou, Xiaona Liu, Jun Guo, Wei Zhang, Zhongtao World J Surg Oncol Research BACKGROUND: Pancreaticoduodenectomy (PD) remains the major curative operation for malignant neoplasm of pancreas or cancerous tumors near the pancreas. Despite advancements in recent years, the postoperative recurrence rate of these neoplasms and tumors remains high. Moreover, overall morbidity remains high due to clinically relevant postoperative pancreatic fistula (POPF). METHODS: To compare the clinical outcomes of modified invaginated anastomosis and mucosa-to-mucosa anastomosis, this retrospective study included 343 patients who underwent PD from January 2008 to January 2019 at Beijing Friendship Hospital, Capital Medical University. The patients’ general conditions and disease status were preoperatively evaluated. The surgical procedure was recorded, and operative management was appropriately performed. RESULTS: Compared with mucosa-to-mucosa anastomosis, modified invaginated anastomosis resulted in a higher intraoperative blood transfusion rate (P < 0.001) and lower hospitalization expenses (P = 0.049). However, no significant differences were found in operation time (P = 0.790), intraoperative bleeding (P = 0.428), postoperative recovery exhaust time (P = 0.442), time to normal flow of food (P = 0.163), and hospitalization time (P = 0.567). Operation time was a risk factor for POPF (odds ratio 1.010; 95% confidence interval 1.003–1.016; P = 0.003). The incidence of pancreatic fistula (grades B and C) was lower in the patients who underwent modified invaginated anastomosis (14.1%) than in those who underwent mucosa-to-mucosa anastomosis (15.3%). The operation time was greater in the POPF group than in the non POPF group among the patients who received modified invaginated anastomosis (P = 0.003) and mucosa-to-mucosa anastomosis (P = 0.002). CONCLUSION: Modified invaginated pancreaticojejunostomy for PD resulted in a decreased incidence of POPF; it may serve as a new approach for PD while managing patients who have undergone PD. BioMed Central 2020-04-15 /pmc/articles/PMC7161299/ /pubmed/32295594 http://dx.doi.org/10.1186/s12957-020-01851-6 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Wang, Dong
Liu, Xiao
Wu, Hongwei
Liu, Kun
Zhou, Xiaona
Liu, Jun
Guo, Wei
Zhang, Zhongtao
Clinical evaluation of modified invaginated pancreaticojejunostomy for pancreaticoduodenectomy
title Clinical evaluation of modified invaginated pancreaticojejunostomy for pancreaticoduodenectomy
title_full Clinical evaluation of modified invaginated pancreaticojejunostomy for pancreaticoduodenectomy
title_fullStr Clinical evaluation of modified invaginated pancreaticojejunostomy for pancreaticoduodenectomy
title_full_unstemmed Clinical evaluation of modified invaginated pancreaticojejunostomy for pancreaticoduodenectomy
title_short Clinical evaluation of modified invaginated pancreaticojejunostomy for pancreaticoduodenectomy
title_sort clinical evaluation of modified invaginated pancreaticojejunostomy for pancreaticoduodenectomy
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7161299/
https://www.ncbi.nlm.nih.gov/pubmed/32295594
http://dx.doi.org/10.1186/s12957-020-01851-6
work_keys_str_mv AT wangdong clinicalevaluationofmodifiedinvaginatedpancreaticojejunostomyforpancreaticoduodenectomy
AT liuxiao clinicalevaluationofmodifiedinvaginatedpancreaticojejunostomyforpancreaticoduodenectomy
AT wuhongwei clinicalevaluationofmodifiedinvaginatedpancreaticojejunostomyforpancreaticoduodenectomy
AT liukun clinicalevaluationofmodifiedinvaginatedpancreaticojejunostomyforpancreaticoduodenectomy
AT zhouxiaona clinicalevaluationofmodifiedinvaginatedpancreaticojejunostomyforpancreaticoduodenectomy
AT liujun clinicalevaluationofmodifiedinvaginatedpancreaticojejunostomyforpancreaticoduodenectomy
AT guowei clinicalevaluationofmodifiedinvaginatedpancreaticojejunostomyforpancreaticoduodenectomy
AT zhangzhongtao clinicalevaluationofmodifiedinvaginatedpancreaticojejunostomyforpancreaticoduodenectomy